Non-Serious COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Non-Serious COVID-19) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Rheumatoid arthritis, Psoriatic arthritis and Panuveitis.    No Medical History information was reported.   In June 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In July 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In March 2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) UNK, Citrate Free. On an unknown date, the patient experienced COVID-19 (Non-Serious COVID-19). At the time of the report, COVID-19 (Non-Serious COVID-19) was resolving.            Concomitant medication was not provided. It was unknown if patient was enrolled in a COVID-19 Vaccine trial. Treatment information was not reported. The reporter causality for event of Covid with Humira was no reasonable possibility. Company comment This is a spontaneous case reported by a consumer, concerning a 50-year-old female patient with no relevant medical history reported, who experienced the unexpected, non serious AESI of Covid 19, unknown days after receiving the 3 dose of mRNA 1273 vaccine in the covid 19 vaccination series. Patient received the primary 2 doses with Moderna vaccines at an interval of 1 month, with the last dose taken about 7 months prior to the 3 dose. It was reported that the patient was taking Adalimumab (humira) from an unknown date for Rheumatoid arthritis, Psoriatic arthritis and Panuveitis. No information was provided on other symptoms, clinical course, labs, diagnostic investigations and treatment. The event was resolving. Concomitant use of Adalimumab for multiple auto immune disorders is a confounder The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This is a spontaneous case reported by a consumer, concerning a 50-year-old female patient with no relevant medical history reported, who experienced the unexpected, non serious AESI of Covid 19, unknown days after receiving the 3 dose of mRNA 1273 vaccine in the covid 19 vaccination series. Patient received the primary 2 doses with Moderna vaccines at an interval of 1 month, with the last dose taken about 7 months prior to the 3 dose. It was reported that the patient was taking Adalimumab (humira) from an unknown date for Rheumatoid arthritis, Psoriatic arthritis and Panuveitis. No information was provided on other symptoms, clinical course, labs, diagnostic investigations and treatment. The event was resolving. Concomitant use of Adalimumab for multiple auto immune disorders is a confounder The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per medical judgement.